Trials / Active Not Recruiting
Active Not RecruitingNCT06289998
Study of Tamibarotene in Patients With ADPKD
Phase IIa Clinical Trial of Tamibarotene in Patients With Autosomal Dominant Polycystic Kidney Disease
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- Sponsor
- Rege Nephro Co., Ltd. · Industry
- Sex
- All
- Age
- 26 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
Clinical trial of tamibarotene in patients with Autosomal Dominant Polycystic Kidney Disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tamibarotene | Subjects are administrated to tamibarotene 4 mg in daily for 52 weeks. |
| DRUG | Placebo | Subjects are administrated to placebo in daily for 52 weeks. |
Timeline
- Start date
- 2023-12-22
- Primary completion
- 2025-12-01
- Completion
- 2025-12-01
- First posted
- 2024-03-04
- Last updated
- 2025-04-04
Locations
8 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT06289998. Inclusion in this directory is not an endorsement.